TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).


Options:
A: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Mono Unsaturated Fatty Acids in Obesity; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Intervention Type: BEHAVIORAL; Name: High or low Glycemic Index and high or low Protein Diet; Assigned to Arm(s): 1, 2, 3, 4, 5
D: Arm Label: DASH diet; Type: EXPERIMENTAL; Interventions: Behavioral: DASH diet | Arm Label: DASH diet plus Weight loss; Type: EXPERIMENTAL; Interventions: Behavioral: DASH diet plus Weight loss | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: DASH diet; Assigned to Arm(s): DASH diet | Intervention Type: BEHAVIORAL; Name: DASH diet plus Weight loss; Assigned to Arm(s): DASH diet plus Weight loss

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).


Options:
A: Intervention Type: OTHER; Name: Fructose; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
C: Arm Label: 0% aspartame (water); Type: EXPERIMENTAL; Interventions: Other: water | Arm Label: 5 mg aspartame; Type: EXPERIMENTAL; Interventions: Other: aspartame | Arm Label: 15mg aspartame; Type: EXPERIMENTAL; Interventions: Other: aspartame | Intervention Type: OTHER; Name: aspartame; Assigned to Arm(s): 15mg aspartame, 5 mg aspartame | Intervention Type: OTHER; Name: water; Assigned to Arm(s): 0% aspartame (water)
D: Arm Label: Vegan Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Intervention Meetings, Behavioral: Physical Activity, Behavioral: Podcasts/Mailings | Arm Label: Omnivorous (Omni) Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Intervention Meetings, Behavioral: Physical Activity, Behavioral: Podcasts/Mailings | Intervention Type: BEHAVIORAL; Name: Dietary Intervention Meetings; Assigned to Arm(s): Omnivorous (Omni) Diet, Vegan Diet | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Omnivorous (Omni) Diet, Vegan Diet | Intervention Type: BEHAVIORAL; Name: Podcasts/Mailings; Assigned to Arm(s): Omnivorous (Omni) Diet, Vegan Diet

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).


Options:
A: Arm Label: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug); Type: ACTIVE_COMPARATOR; Interventions: Drug: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo | Arm Label: Placebo Tablet; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo; Assigned to Arm(s): Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Tablet
B: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin C; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beta-carotene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: folic acid/Vitamin B6/Vitamin B12; Assigned to Arm(s): N/A
D: Arm Label: Vitamin E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin E | Arm Label: Vitamin C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin C | Arm Label: Multivitamin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin | Arm Label: Beta-carotene; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beta-carotene | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): Vitamin E | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin C; Assigned to Arm(s): Vitamin C | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin; Assigned to Arm(s): Multivitamin | Intervention Type: DIETARY_SUPPLEMENT; Name: Beta-carotene; Assigned to Arm(s): Beta-carotene

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zodin (drug) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olive oil (placebo) | Intervention Type: DRUG; Name: Zodin (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Olive oil (placebo); Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
C: Arm Label: EPA + DHA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: EPA + DHA plus ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: margarine spread | Intervention Type: DIETARY_SUPPLEMENT; Name: margarine spread; Assigned to Arm(s): ALA, EPA + DHA, EPA + DHA plus ALA, Placebo
D: Intervention Type: BEHAVIORAL; Name: Four Diets Differing in Macronutrient Composition; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Diets Low in Saturated Fat; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).


Options:
A: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A or Beta-Carotene Supplements; Assigned to Arm(s): 1, 2, 3
C: Arm Label: telephone; Type: EXPERIMENTAL; Interventions: Behavioral: telephone | Arm Label: face-to-face; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: consultation face-to-face | Intervention Type: BEHAVIORAL; Name: telephone; Assigned to Arm(s): telephone | Intervention Type: BEHAVIORAL; Name: consultation face-to-face; Assigned to Arm(s): face-to-face
D: Arm Label: Culturally-tailored video; Type: OTHER; Interventions: Behavioral: Culturally-tailored video | Intervention Type: BEHAVIORAL; Name: Culturally-tailored video; Assigned to Arm(s): Culturally-tailored video

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).


Options:
A: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
B: Arm Label: Intervention; Type: N/A; Interventions: Behavioral: educational/counseling intervention, Behavioral: therapeutic dietary intervention | Arm Label: Control; Type: N/A; Interventions: Behavioral: therapeutic dietary intervention | Intervention Type: BEHAVIORAL; Name: educational/counseling intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: therapeutic dietary intervention; Assigned to Arm(s): Control, Intervention
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Intervention Type: BEHAVIORAL; Name: Low-fat, low-Glycemic Index, vegan diet; Assigned to Arm(s): 1, 2
D: Arm Label: High MUFA diet; Type: EXPERIMENTAL; Interventions: Other: High-MUFA diet | Arm Label: High CHO diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High-CHO diet | Intervention Type: OTHER; Name: High-MUFA diet; Assigned to Arm(s): High MUFA diet | Intervention Type: OTHER; Name: High-CHO diet; Assigned to Arm(s): High CHO diet

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).


Options:
A: Arm Label: Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Combination Clopidogrel and asprin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Asprin and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of clopidogrel and Asprin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination Clopidogrel and asprin | Intervention Type: DRUG; Name: Placebo of clopidogrel and Asprin; Assigned to Arm(s): Asprin and placebo
C: Arm Label: Canakinumab Dose 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab, Drug: Standard of care | Arm Label: Canakinumab Dose 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab, Drug: Standard of care | Arm Label: Canakinumab Dose 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab, Drug: Standard of care | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Standard of care | Intervention Type: DRUG; Name: Canakinumab; Assigned to Arm(s): Canakinumab Dose 150 mg, Canakinumab Dose 300 mg, Canakinumab Dose 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Standard of care; Assigned to Arm(s): Canakinumab Dose 150 mg, Canakinumab Dose 300 mg, Canakinumab Dose 50 mg, Placebo
D: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).


Options:
A: Arm Label: Switch to Zoladex + AI for 3-2 years; Type: EXPERIMENTAL; Interventions: Drug: Zoladex+AI | Arm Label: TAM; Type: EXPERIMENTAL; Interventions: Drug: TAM | Intervention Type: DRUG; Name: Zoladex+AI; Assigned to Arm(s): Switch to Zoladex + AI for 3-2 years | Intervention Type: DRUG; Name: TAM; Assigned to Arm(s): TAM
B: Arm Label: Combination; Type: EXPERIMENTAL; Interventions: Drug: Goserelin | Arm Label: Conctrol; Type: ACTIVE_COMPARATOR; Interventions: Drug: tamoxifen | Intervention Type: DRUG; Name: tamoxifen; Assigned to Arm(s): Conctrol | Intervention Type: DRUG; Name: Goserelin; Assigned to Arm(s): Combination
C: Arm Label: TAM+OFS(E) group; Type: EXPERIMENTAL; Interventions: Drug: goserelin, Drug: tamoxifen | Arm Label: TAM(D) group; Type: ACTIVE_COMPARATOR; Interventions: Drug: tamoxifen | Arm Label: Permanent postmenopausal(A) group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: TAM(B); Type: ACTIVE_COMPARATOR; Interventions: Drug: tamoxifen | Arm Label: TAM+OFS (C); Type: EXPERIMENTAL; Interventions: Drug: goserelin, Drug: tamoxifen | Intervention Type: DRUG; Name: goserelin; Assigned to Arm(s): TAM+OFS (C), TAM+OFS(E) group | Intervention Type: DRUG; Name: tamoxifen; Assigned to Arm(s): TAM(B), TAM(D) group, TAM+OFS (C), TAM+OFS(E) group
D: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A

Answer: D